129 related articles for article (PubMed ID: 33393135)
1. Influence of switching from intravenous to oral administration on serum voriconazole concentration.
Harada S; Niwa T; Hoshino Y; Fujibayashi A; Suzuki A
J Clin Pharm Ther; 2021 Jun; 46(3):780-785. PubMed ID: 33393135
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of voriconazole in hospitalised patients.
Veringa A; Geling S; Span LF; Vermeulen KM; Zijlstra JG; van der Werf TS; Kosterink JG; Alffenaar JC
Int J Antimicrob Agents; 2017 Feb; 49(2):243-246. PubMed ID: 28012684
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients.
Imataki O; Yamaguchi K; Uemura M; Fukuoka N
Transpl Infect Dis; 2018 Aug; 20(4):e12886. PubMed ID: 29570914
[TBL] [Abstract][Full Text] [Related]
4. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
[TBL] [Abstract][Full Text] [Related]
10. Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class C).
Yamada T; Imai S; Koshizuka Y; Tazawa Y; Kagami K; Tomiyama N; Sugawara R; Yamagami A; Shimamura T; Iseki K
Biol Pharm Bull; 2018 Jul; 41(7):1112-1118. PubMed ID: 29760306
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.
Mori M; Kobayashi R; Kato K; Maeda N; Fukushima K; Goto H; Inoue M; Muto C; Okayama A; Watanabe K; Liu P
Antimicrob Agents Chemother; 2015 Feb; 59(2):1004-13. PubMed ID: 25451051
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.
Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E
Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of voriconazole after intravenous and oral administration to healthy cats.
Vishkautsan P; Papich MG; Thompson GR; Sykes JE
Am J Vet Res; 2016 Sep; 77(9):931-9. PubMed ID: 27580104
[TBL] [Abstract][Full Text] [Related]
14. Inflammation is associated with voriconazole trough concentrations.
van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2014 Dec; 58(12):7098-101. PubMed ID: 25223994
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated With Voriconazole Concentration in Pediatric Patients.
Kang S; Yee J; Kim JY; Han HW; Kang SO; Lee KE; Gwak HS
Ther Drug Monit; 2020 Dec; 42(6):866-871. PubMed ID: 32868633
[TBL] [Abstract][Full Text] [Related]
16. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Wang X; Zhao J; Wen T; Liao X; Luo B
Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole: How to Use This Antifungal Agent and What to Expect.
Malani AN; Kerr LE; Kauffman CA
Semin Respir Crit Care Med; 2015 Oct; 36(5):786-95. PubMed ID: 26398543
[TBL] [Abstract][Full Text] [Related]
18. Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients.
Chayakulkeeree M; Poovipirom N; Siengwattana P; Maneerattanaporn M
J Med Assoc Thai; 2015 Mar; 98(3):232-7. PubMed ID: 25920292
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
Kadam RS; Van Den Anker JN
Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre.
Boast A; Curtis N; Cranswick N; Gwee A
J Antimicrob Chemother; 2016 Jul; 71(7):2031-6. PubMed ID: 27009030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
